Претраживање
Приказ резултата 1-10 од 42
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells
(Amer Soc Hematology, Washington, 2008)
Hydroxyurea, a drug widely used for treating myeloproliferative diseases, has also been approved for the treatment of sickle cell disease by raising fetal hemoglobin (HbF). We have shown that nitric oxide (NO) and the ...
Transcriptional profiling of human erythroid progenitors from g-csf mobilized and nonmobilized peripheral blood
(Ferrata Storti Foundation, Pavia, 2013)
Addition of the degree of bone marrow fibrosis to IPSS in new scoring system improve prediction of survival in primary myelofibrosis
(Ferrata Storti Foundation, Pavia, 2013)
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
(Amer Soc Hematology, Washington, 2019)
Increased energy requirement and metabolic reprogramming are hallmarks of cancer cells. We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis of mutant JAK2-driven myeloproliferative ...
Hypoxia inducible genes, erythropoietin and vascular endothelial growth factor expression in renal cell carcinoma
(Ferrata Storti Foundation, Pavia, 2013)
Gene and protein expression analyses of the mtor signaling pathway in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2015)
Predictors of survival in patients with essential thrombocythemia
(Ferrata Storti Foundation, Pavia, 2015)
Oxidative stress in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2014)
Proinflammatory cytokine il-6 stimulation of angiogenic factors and DNA replication is blocked by jak-stat pathway inhibition in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2017)